

We claim:

1. A pharmaceutical composition which comprises a first component which is an atypical antipsychotic and a second component which is mGlu2/3 receptor agonist.

2. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is an atypical antipsychotic, in combination with an amount of a second component which is a mGlu2/3 receptor agonist.

3. A pharmaceutical composition which comprises a first component which is clozapine and a second component which is (1R,4S,5S,6S)-4-[(2'S)-(2'-Amino)-propionyl]amino-(2-sulfonylbicyclo[3.1.0]hexane)-4,6-dicarboxylic acid.

4. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is clozapine, in combination with an amount of a second component which is (1R,4S,5S,6S)-4-[(2'S)-(2'-Amino)-propionyl]amino-(2-sulfonylbicyclo[3.1.0]hexane)-4,6-dicarboxylic acid.

5. A pharmaceutical composition which comprises a first component which is clozapine and a second component which is (1R, 4R, 5S, 6R)-4-amino-(2-oxabicyclo[3.1.0]hexane)-4,6-dicarboxylic acid.

6. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is clozapine, in combination with an amount of a second component which is (1R, 4R, 6S, 6R)-4-amino-(2-oxabicyclo[3.1.0]hexane)-4,6-dicarboxylic acid.

7. A pharmaceutical composition which comprises a first component which is clozapine and a second component which is (1S, 2R, 4S, 5S, 6S)-2-amino-4-fluoro bicyclo[3.1.0]hexane-2,6-dicarboxylic acid.

8. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is clozapine in combination with an amount of a second component which is (1S, 2R, 4S, 5S, 6S)-2-amino-4-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid.

9. A pharmaceutical composition which comprises a first component which is clozapine and a second component which is (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid.

10. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is clozapine in combination with an amount of a second component which is (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid.

11. A pharmaceutical composition which comprises a first component which is olanzapine and a second component which is (1R,4S,5S,6S)-4-[(2'S)-(2'-Amino)-propionyl]amino-(2-sulfonylbicyclo[3.1.0]hexane)-4,6-dicarboxylic acid.

12. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is olanzapine in combination with an amount of a second component which is (1R,4S,5S,6S)-4-[(2'S)-(2'-Amino)-propionyl]amino-(2-sulfonylbicyclo[3.1.0]hexane)-4,6-dicarboxylic acid.

13. A pharmaceutical composition which comprises a first component which is olanzapine and a second component which is (1R, 4R, 5S, 6R)-4-amino-(2-oxabicyclo[3.1.0]hexane)-4,6-dicarboxylic acid.

14. A method for treating a patient suffering from a susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first

component which is olanzapine in combination with an amount of a second component which is (1R, 4R, 5S, 6R)-4-amino-(2-oxabicyclo [3.1.0]hexane)-4,6-dicarboxylic acid.

15. A pharmaceutical composition which comprises a first component which is olanzapine and a second component which is (1S, 2R, 4S, 6S)-2-amino-4-fluorobicyclo[3.1.0]hexane -2,6-dicarboxylic acid.

16. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is olanzapine in combination with an amount of a second component which is (1S, 2R, 4S, 6S)-2-amino-4-fluorobicyclo[3.1.0]hexane -2,6-dicarboxylic acid.

17. A pharmaceutical composition which comprises a first component which is olanzapine and a second component which is (+)-2-aminobicyclo[3.1.0] hexane -2,6-dicarboxylic acid.

18. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is olanzapine in combination with an amount of a second component which is (+)-2-aminobicyclo[3.1.0] hexane -2,6- dicarboxylic acid.

19. A pharmaceutical composition which comprises a first component which is an atypical antipsychotic and a second component which is a compound which allosterically enhances receptor activity for mGlu2 or mGlu3.

20. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is an atypical antipsychotic in combination with an amount of a second component which is a compound which allosterically enhances receptor activity for mGlu2 or mGlu3.

21. A pharmaceutical composition which comprises a first component which is an atypical antipsychotic and a second component which is a compound which allosterically enhances receptor activity for mGlu2 and mGlu3.

5 22. A method for treating a patient suffering from or susceptible to a psychiatric disorder, comprising administering to said patient an amount of a first component which is an atypical antipsychotic in combination with an amount of a second component which is a compound which allosterically enhances receptor activity for mGlu2 and mGlu3.

10